Sato Vicki L 的 Form 4 申報
Denali Therapeutics Inc.（DNLI），2021/9/17 申報
- 申報編號
- 0001714899-21-000091
- 申報時間
- 2021/9/17
- 交易日
- 2021/9/15
- 申報延遲
- 2 天
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
這份申報列了 4 筆非衍生性交易。公開市場賣出合計 $8.90 萬。交易後 2 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Sato Vicki LCIK 0001197020 | 董事 |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F2
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $51.56 to $52.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
- F4
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $52.56 to $53.48 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
- F5
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $53.57 to $54.55 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
表 I 有 1 筆交易的價格引用這則附註。
- F6
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $54.63 to $54.89 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
表 I 有 1 筆交易的價格引用這則附註。